Depomed, Inc. stock price, DEPO

Depomed, Inc. stock chart:



Depomed, Inc. close price: 18.48

Stock price forecast:

UP TO +14.34%
Target: 21.13

Total forecasts: 90
Reached: 58 (64.44%)

Total Win: 87.06 (435.24%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90915964.84%89.144.88%611.36-20.00-3.27%69.143.78%
3031929.03%27.955.02%418.50-11.94-2.85%16.012.76%
141500.00%0.000.00%288.05-10.85-3.77%-10.85-3.77%
7800.00%0.000.00%150.17-2.33-1.55%-2.33-1.55%

Showing 1-10 of 324 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-01-1918.4821.160000-00-00
2017-01-1818.4621.260000-00-00
2017-01-1718.8821.40000-00-00
2017-01-1618.8821.680000-00-00
2017-01-1518.8821.610000-00-00
2017-01-1418.8821.660000-00-00
2017-01-1318.8121.660000-00-00
2017-01-1218.921.870000-00-00
2017-01-1118.9622.070000-00-00
2017-01-1019.1822.360000-00-00

Depomed, Inc. latest news:


  • 11/07/2016 14:31:34

    Depomed plummets after disappointing sales of painkillers

    Depomed Inc. fell more than 12% in late trading Monday after a disappointing quarterly earnings report that showed weaker than expected sales for the company's two biggest drugs. Depomed reported a net loss of $12.9 million, or 21 cents a share, on sales of $110.5 million; after adjustments for stock-based compensation and other factors, Depomed claimed profit of 28 cents a share. Analysts polled by FactSet expected Depomed to report adjusted profit of 35 cents a share on sales of $126.8 million. The shortfall came from weak sales of painkillers Nucynta and Gralise, which came in at $65.3 million and $20.6 million, well below projections from Depomed and analysts. "Although our third quarter revenues increased by 5% over the previous year's quarter, they did not meet our expectations, as several factors, including a disconnect between prescription demand and wholesaler shipments, influenced net sales of the Nucynta franchise and Gralise," Chief Executive Jim Schoeneck explained in Monday's announcement. Depomed shares -- which have been volatile all year due to an activist-investor campaign, acquisition attempt, a big court win and reports of a potential sale effort -- fell to less than $20.50 in late trading, after closing with a 1% gain at $22.89.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Derma Sciences, Inc.DSCI | Dermira, Inc.DERM | Destination Maternity CorporationDEST | Destination XL Group, Inc.DXLG | Deswell Industries, Inc.DSWL | Dex Media, Inc.DXM | DexCom, Inc.DXCM | DHX Media Ltd.DHXM | Diamond Foods, Inc.DMND | Diamond Hill Investment Group, Inc.DHIL |